#1 Clinical Trials Search in Europe

BROLUCIZUMAB

Brolucizumab (marketed as BEOVU) is a newer anti-VEGF (vascular endothelial growth factor) medication used to treat neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). This article examines how brolucizumab has been studied in clinical trials, its effectiveness compared to other treatments, dosing regimens, and safety profile. For patients considering treatment options for macular degeneration, understanding the clinical evidence behind brolucizumab can help inform discussions with healthcare providers about this therapeutic option.

# BROLUCIZUMAB (BEOVU): A Comprehensive Guide for Patients Table of Contents – [What is Brolucizumab?](#what-is-brolucizumab) – [How Brolucizumab Works](#how-brolucizumab-works) – [Medical Conditions Treated with Brolucizumab](#medical-conditions-treated-with-brolucizumab) – [Administration and Dosing](#administration-and-dosing) – [Efficacy and Benefits](#efficacy-and-benefits) – [Treatment Regimens](#treatment-regimens) – [Side Effects and Safety](#side-effects-and-safety) – [Comparison with Other Treatments](#comparison-with-other-treatments) – [Patient Considerations](#patient-considerations) What is Brolucizumab? Brolucizumab (brand name BEOVU®) is a medication used to treat eye diseases, primarily neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It belongs to a class of medications known as anti-VEGF (anti-vascular endothelial growth factor) agents [1]. This medication is relatively new to the market compared to other anti-VEGF treatments. Brolucizumab is a humanized single-chain antibody fragment (scFv) that inhibits vascular endothelial growth factor A (VEGF-A). It is also known by research codes RTH258 and ESBA1008 during its development phase [2]. The medication is delivered as an intravitreal injection, meaning it is injected directly into the eye. How Brolucizumab Works Brolucizumab works by targeting and inhibiting VEGF-A, a protein that promotes the growth of abnormal blood vessels in the eye. In conditions like wet AMD and DME, these abnormal blood vessels can leak fluid and blood into the retina, causing vision problems [3]. The key characteristics of brolucizumab that distinguish it from other anti-VEGF agents include: – **Smaller molecule size**: As a single-chain antibody fragment, brolucizumab is much smaller than other anti-VEGF medications, which may allow for better tissue penetration and higher dosing concentration [4]. – **Higher molar concentration**: Due to its smaller size, more molecules of brolucizumab can be delivered in a single injection compared to other anti-VEGF drugs, potentially providing longer-lasting effects [5]. – **Tissue penetration**: The smaller size may enable better penetration through the layers of the retina to reach the targeted tissues [3]. Medical Conditions Treated with Brolucizumab Brolucizumab is primarily used to treat: # Neovascular (Wet) Age-Related Macular Degeneration Wet AMD is characterized by the growth of abnormal blood vessels under the macula (the central part of the retina responsible for detailed central vision). These vessels can leak fluid and blood, causing distortion and loss of central vision [1]. # Diabetic Macular Edema DME occurs when blood vessels in the retina leak fluid into the macula due to complications from diabetes. This causes the macula to swell, which can blur and distort central vision [6]. # Macular Polypoidal Choroidal Vasculopathy (PCV) Some clinical trials have also examined brolucizumab’s effectiveness in treating PCV, a subtype of AMD characterized by abnormal vessel networks with polyp-like dilations [7]. # Dystrophy-Related Macular Neovascularization Research has been conducted on using brolucizumab for dystrophy-related macular neovascular degeneration, which is a vision-threatening condition [8]. Administration and Dosing Brolucizumab is administered through intravitreal injection, meaning it is injected directly into the eye’s vitreous humor (the gel-like substance that fills the eyeball). This procedure is typically performed in an ophthalmologist’s office after the eye has been numbed with local anesthetic drops [1]. The standard dosing options include: – **For nAMD**: 6 mg (0.05 mL of solution) per eye [1] – **For DME**: Studies have evaluated both 3 mg and 6 mg doses, with 6 mg being the most common [6] The medication is available as a pre-filled syringe for single use only, containing 6 mg of brolucizumab in 0.05 mL of solution (120 mg/mL) [5]. Efficacy and Benefits Multiple clinical trials have demonstrated the efficacy of brolucizumab in treating both nAMD and DME. Key benefits include: # Visual Acuity Improvement Patients treated with brolucizumab have shown improvements in best-corrected visual acuity (BCVA), which is the clearest vision possible with correction such as glasses [9]. For example, a significant number of patients gained 15 or more letters on standardized eye charts after treatment [10]. # Anatomical Improvements Brolucizumab has demonstrated strong ability to reduce retinal fluid, including: – **Reduction in central subfield thickness (CSFT)**: Measurement of the thickness of the central retina, with reductions indicating decreased swelling [11] – **Resolution of intraretinal fluid (IRF) and subretinal fluid (SRF)**: Many patients achieve complete fluid resolution, which is important for long-term visual outcomes [9] # Duration of Effect One of brolucizumab’s key advantages is its potential for longer intervals between treatments for many patients [12]. This is particularly beneficial for reducing treatment burden. # Disease Activity Control Studies have shown that brolucizumab can effectively control disease activity, with a significant proportion of patients maintaining stable disease on extended treatment intervals [13]. Treatment Regimens Brolucizumab is typically administered following specific regimens designed to maximize effectiveness while minimizing the number of injections: # Loading Phase Treatment usually begins with a loading phase consisting of: – For nAMD: Three monthly injections (at weeks 0, 4, and 8) [1] – For DME: Five loading doses at 6-week intervals have been studied [14] # Maintenance Phase After the loading phase, several maintenance regimens are possible: Fixed Interval Some patients follow a fixed schedule, typically: – Every 8 weeks (q8w) or – Every 12 weeks (q12w) [1] Treat-and-Extend (T&E) This personalized approach involves: – Starting with fixed intervals after the loading phase – Gradually extending the time between injections (by 2-4 weeks) if the disease remains stable – Reducing intervals if signs of disease activity appear [15] Personalized Treatment Interval Some studies have examined personalized treatment approaches where: – Treatment intervals are determined based on individual patient response – Some patients may achieve treatment intervals of up to 16-20 weeks [7] – Disease activity assessments (DAAs) are conducted to determine whether treatment intervals should be extended, maintained, or shortened [16] Side Effects and Safety As with any medication, brolucizumab can cause side effects. It’s important for patients to be aware of these potential effects and to report any concerning symptoms to their healthcare provider promptly. # Common Side Effects The most common side effects associated with brolucizumab include: – **Eye redness** (conjunctival hyperemia) – **Eye pain** – **Floaters** (small dark spots or squiggly lines in vision) – **Increased intraocular pressure** (temporary after injection) – **Eye discomfort or irritation** [7] # Serious Side Effects More serious, but less common, side effects that require immediate medical attention include: – **Intraocular inflammation (IOI)**: Inflammation inside the eye that may present as eye pain, increased sensitivity to light, or changes in vision [1] – **Retinal vasculitis**: Inflammation of the blood vessels in the retina [17] – **Retinal vascular occlusion**: Blockage of blood vessels in the retina that can lead to vision loss [17] – **Endophthalmitis**: Serious infection inside the eye, which is rare but can occur with any intravitreal injection [18] # Monitoring and Management To ensure safety during treatment: – Regular follow-up appointments are essential to monitor for any signs of side effects – Patients should report any new eye symptoms promptly – Physicians may conduct specific tests to evaluate eye health during and after treatment [19] # Safety Profile Safety data from clinical trials and real-world studies provide information on the incidence of adverse events. While most patients tolerate brolucizumab well, awareness of potential side effects is important for both patients and healthcare providers [7]. Comparison with Other Treatments Brolucizumab is one of several anti-VEGF medications used to treat nAMD and DME. Understanding how it compares to other treatments can help patients and doctors make informed decisions. # Compared to Aflibercept (Eylea) Aflibercept is another commonly used anti-VEGF medication. Studies comparing brolucizumab to aflibercept have shown: – Similar improvements in visual acuity – Potentially superior fluid resolution with brolucizumab – Longer treatment intervals possible with brolucizumab for some patients – Different safety profiles that should be considered when selecting treatment [20] # Compared to Ranibizumab (Lucentis) Ranibizumab was one of the first anti-VEGF medications approved for eye conditions. Compared to ranibizumab, brolucizumab: – May allow for less frequent injections in some patients – Has shown comparable visual acuity outcomes – Has a different molecular structure (smaller size) that may affect tissue penetration [5] # Treatment Selection Considerations Factors that may influence the choice between brolucizumab and other anti-VEGF treatments include: – Individual patient response to previous treatments – Presence of persistent fluid despite treatment with other agents – Patient preference regarding treatment frequency – Specific patient risk factors for potential side effects [21] Patient Considerations When considering brolucizumab treatment, patients should be aware of several important factors: # Treatment Expectations – **Treatment Duration**: Anti-VEGF therapy, including brolucizumab, is typically a long-term treatment. Most patients with nAMD or DME will need ongoing injections to maintain vision gains and prevent disease progression [22]. – **Follow-up Requirements**: Regular follow-up appointments are essential for monitoring treatment response and adjusting treatment intervals as needed. – **Gradual Improvement**: Vision improvement may be gradual, and maximum benefits may take several months to achieve [23]. # Quality of Life Impact Studies using the Visual Function Questionnaire-25 (VFQ-25) have shown improvements in vision-related quality of life with brolucizumab treatment, including benefits in: – Near and distance activities – Social functioning – Mental health – Dependency – Driving [24] # Cost and Access – **Insurance Coverage**: Coverage for brolucizumab varies by insurance plan and country. Patients should check with their insurance provider regarding coverage details. – **Patient Assistance Programs**: Some pharmaceutical companies offer assistance programs for eligible patients who have difficulty affording their medications. – **Healthcare System Variation**: Availability and coverage of brolucizumab may vary significantly between countries and healthcare systems [25]. ### Shared Decision Making The decision to use brolucizumab should involve: – **Discussion of Benefits and Risks**: Patients should understand both potential benefits and possible side effects. – **Consideration of Alternatives**: Discussion of other available treatment options. – **Patient Preferences**: Consideration of patient preferences regarding treatment frequency and goals [24]. Brolucizumab represents an important treatment option for patients with nAMD and DME. By understanding the medication’s mechanism, benefits, risks, and treatment process, patients can participate more actively in decisions about their eye care and treatment plan.
Aspect Information
Drug Overview Brolucizumab (BEOVU) is an anti-VEGF medication administered as an intravitreal injection to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). It’s a single-chain antibody fragment that inhibits VEGF, reducing abnormal blood vessel growth and fluid leakage in the retina.
Dosing Protocol Standard dosing: 6 mg intravitreal injection, starting with 3 monthly loading doses (weeks 0, 4, 8), followed by maintenance injections every 8-12 weeks based on disease activity. Some protocols explore extended intervals up to 16-20 weeks using treat-and-extend approaches.
Efficacy Clinical trials demonstrate non-inferiority to aflibercept in visual acuity improvements for nAMD and DME. Brolucizumab shows superior fluid resolution in some patients and allows for less frequent dosing (q12w) in approximately 50-60% of patients after the loading phase.
Anatomical Benefits Superior reduction in central subfield thickness (CSFT) compared to aflibercept in several trials. Better resolution of intraretinal fluid (IRF) and subretinal fluid (SRF), particularly in patients with persistent fluid despite prior anti-VEGF treatment.
Safety Concerns Common side effects include injection-related discomfort. More serious adverse events include intraocular inflammation (IOI), retinal vasculitis, and retinal vascular occlusion. Safety monitoring was emphasized in trials following post-marketing reports of inflammatory events.
Treatment Burden Potential advantage of reduced treatment burden with fewer injections needed (q12w vs q8w) for many patients compared to other anti-VEGF treatments. This may improve treatment adherence and reduce healthcare resource utilization.
Special Populations Studies included evaluation in various populations, including treatment-naïve patients, those switching from other anti-VEGF treatments, and patients with specific conditions like polypoidal choroidal vasculopathy (PCV) and pachychoroid neovasculopathy.
Quality of Life Several trials measured vision-related quality of life using the VFQ-25 questionnaire, showing improvements consistent with visual gains. Extended treatment intervals may reduce treatment burden and improve patient satisfaction.

FAQ

  • What is brolucizumab (BEOVU) and how does it work? Brolucizumab (BEOVU) is an anti-VEGF (vascular endothelial growth factor) medication administered by intravitreal injection for treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). It works by inhibiting VEGF, a protein that promotes the growth of abnormal blood vessels in the retina. By blocking VEGF, brolucizumab helps reduce fluid leakage, swelling, and vision loss associated with these conditions. Compared to other anti-VEGF medications, brolucizumab is a smaller molecule (single-chain antibody fragment), which may allow for greater tissue penetration and higher dose concentration in a single injection.
  • How effective is brolucizumab compared to other treatments like aflibercept? Clinical trials show that brolucizumab is generally non-inferior to aflibercept (Eylea) in terms of vision improvement for patients with nAMD and DME. In studies like HAWK and HARRIER (represented in the clinical trials database), brolucizumab demonstrated comparable improvements in visual acuity while showing superior fluid resolution in some patients. A key advantage of brolucizumab in many trials was the potential for longer treatment intervals – with many patients maintaining a 12-week dosing schedule compared to the standard 8-week schedule for aflibercept. This could mean fewer injections for some patients while maintaining similar visual outcomes.
  • What are the typical dosing schedules for brolucizumab treatment? Brolucizumab is typically administered as a 6 mg intravitreal injection. The standard treatment protocol begins with three monthly loading doses (at weeks 0, 4, and 8), followed by maintenance treatment. During maintenance, patients may receive injections every 8 weeks (q8w) or every 12 weeks (q12w), depending on disease activity. Some trials have explored more personalized approaches, including treat-and-extend regimens where intervals between injections are gradually increased up to 16 or 20 weeks if the disease remains stable. Clinical trials show that approximately 50-60% of patients can maintain a 12-week interval after the loading phase, potentially reducing treatment burden compared to other anti-VEGF medications.
  • What side effects or safety concerns are associated with brolucizumab? Common side effects of brolucizumab include eye redness, pain, and blurred vision related to the injection procedure. More serious safety concerns identified in clinical trials include intraocular inflammation (IOI), retinal vasculitis, and retinal vascular occlusion, which can potentially lead to severe vision loss in rare cases. Several trials have specifically monitored these inflammatory events. Other potential adverse events include elevated intraocular pressure, cataracts, and very rarely, endophthalmitis (eye infection). In 2020, safety concerns regarding inflammatory events led to updated warnings in the medication's label. Patients receiving brolucizumab should report symptoms like eye pain, sensitivity to light, or vision changes promptly to their healthcare provider.
  • Who might benefit most from brolucizumab treatment? Based on clinical trial data, patients who might benefit most from brolucizumab include: 1) Those who require frequent anti-VEGF injections with other medications (like aflibercept or ranibizumab) and could benefit from potentially longer treatment intervals; 2) Patients with persistent fluid despite treatment with other anti-VEGF medications, as brolucizumab has shown superior fluid resolution in some studies; 3) Patients with specific anatomical characteristics such as certain types of CNV (choroidal neovascularization) lesions that respond well to brolucizumab. The decision to use brolucizumab should be individualized, weighing its potential benefits against the risk of inflammatory complications, and considering the patient's specific disease characteristics and treatment history.

Ongoing Clinical Trials on BROLUCIZUMAB

  • Study on Treating Neovascular Age-Related Macular Degeneration with Aflibercept, Ranibizumab, and Brolucizumab for Patients with Active Disease

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

Glossary

  • Age-related Macular Degeneration (AMD): A common eye condition that affects the macula, the central part of the retina responsible for sharp, central vision. AMD causes blurring of central vision needed for activities like reading and driving. The wet (neovascular) form involves abnormal blood vessel growth under the retina.
  • Anti-VEGF: A class of medications that block vascular endothelial growth factor (VEGF), a protein that promotes the growth of abnormal blood vessels. In eye conditions like wet AMD, anti-VEGF drugs reduce fluid leakage and abnormal vessel growth in the retina.
  • BCVA (Best-Corrected Visual Acuity): A measurement of vision using an eye chart while wearing the most accurate corrective lenses. In clinical trials, BCVA is often measured using ETDRS letters (a standardized vision chart), with higher scores representing better vision.
  • Brolucizumab: A single-chain antibody fragment that inhibits vascular endothelial growth factor (VEGF). Marketed as BEOVU, it's used to treat neovascular (wet) age-related macular degeneration and diabetic macular edema through intravitreal injection.
  • CNV (Choroidal Neovascularization): The growth of new, abnormal blood vessels from the choroid (the layer of blood vessels under the retina) into the retina. These vessels can leak fluid and blood, causing vision distortion and loss in wet AMD.
  • CSFT (Central Subfield Thickness): A measurement of the thickness of the central portion of the retina, typically measured using OCT. Reduction in CSFT indicates decreased retinal swelling and is used to evaluate treatment effectiveness.
  • DAA (Disease Activity Assessment): An evaluation performed during clinical trials to determine if a disease (like wet AMD) is active or stable. For eye conditions, this typically involves OCT imaging to check for fluid and other signs of disease activity.
  • Diabetic Macular Edema (DME): A complication of diabetes that causes swelling in the macula due to leaking blood vessels, leading to blurred vision. It's a leading cause of vision loss in people with diabetes.
  • ETDRS (Early Treatment Diabetic Retinopathy Study): A standardized method for measuring visual acuity using specially designed eye charts. Visual acuity is reported as the number of letters a person can read, with scores typically ranging from 0-100 letters.
  • Intraocular Inflammation (IOI): Inflammation inside the eye, which can be a side effect of intravitreal injections. Symptoms may include eye pain, redness, sensitivity to light, and blurred vision.
  • Intravitreal Injection: A procedure where medication is injected directly into the vitreous humor (the gel-like substance in the center of the eye). This route of administration is commonly used for anti-VEGF medications like brolucizumab.
  • IRF (Intraretinal Fluid): Fluid accumulation within the layers of the retina, often seen in wet AMD and DME. The presence of IRF is associated with active disease and may indicate the need for treatment.
  • Neovascular AMD (nAMD): Also called wet AMD, this form of age-related macular degeneration is characterized by the growth of abnormal blood vessels under the retina that can leak fluid and blood, causing rapid vision loss if untreated.
  • OCT (Optical Coherence Tomography): A non-invasive imaging technique that uses light waves to take cross-sectional pictures of the retina. OCT helps doctors identify fluid, measure retinal thickness, and monitor treatment response.
  • OCTA (OCT Angiography): An advanced imaging technique that allows visualization of blood vessels in the retina and choroid without the need for dye injection. It's used to assess CNV lesion characteristics and treatment response.
  • PED (Pigment Epithelial Detachment): A condition where the retinal pigment epithelium (a layer of cells under the retina) separates from the underlying Bruch's membrane. PEDs can be filled with fluid, blood, or fibrovascular material and are common in wet AMD.
  • q8w/q12w: Treatment frequency notations where 'q' means 'every,' so q8w means 'every 8 weeks' and q12w means 'every 12 weeks.' These terms are used to describe medication dosing schedules.
  • Retinal Vasculitis: Inflammation of the blood vessels in the retina, which can be a serious adverse event associated with some intravitreal injections. It can lead to vision loss if not promptly treated.
  • SRF (Subretinal Fluid): Fluid accumulation between the retina and the retinal pigment epithelium (RPE). The presence of SRF indicates active disease in conditions like wet AMD and DME.
  • Treat-and-Extend Regimen: A treatment approach where the interval between injections is gradually increased if the disease remains stable, or decreased if disease activity returns. This personalized approach aims to minimize the number of injections while maintaining disease control.

References

  1. https://clinicaltrials.gov/study/NCT05111743
  2. https://clinicaltrials.gov/study/NCT03917472
  3. https://clinicaltrials.gov/study/NCT04239027
  4. https://clinicaltrials.gov/study/NCT02507388
  5. https://clinicaltrials.gov/study/NCT03386474
  6. https://clinicaltrials.gov/study/NCT03481660
  7. https://clinicaltrials.gov/study/NCT05666804
  8. https://clinicaltrials.gov/study/NCT04690062
  9. https://clinicaltrials.gov/study/NCT04047472
  10. https://clinicaltrials.gov/study/NCT04079231
  11. https://clinicaltrials.gov/study/NCT03481634
  12. https://clinicaltrials.gov/study/NCT04597632
  13. https://clinicaltrials.gov/study/NCT04264819
  14. https://clinicaltrials.gov/study/NCT04058067
  15. https://clinicaltrials.gov/study/NCT04697953
  16. https://clinicaltrials.gov/study/NCT05672979
  17. https://clinicaltrials.gov/study/NCT05082415
  18. https://clinicaltrials.gov/study/NCT05037396
  19. https://clinicaltrials.gov/study/NCT04662944
  20. https://clinicaltrials.gov/study/NCT07096713
  21. https://clinicaltrials.gov/study/NCT04287348
  22. https://clinicaltrials.gov/study/NCT05710471
  23. https://clinicaltrials.gov/study/NCT04764656
  24. https://clinicaltrials.gov/study/NCT04543331
  25. https://clinicaltrials.gov/study/NCT05774926